Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of SHR-9839 alone or with chemotherapy and adebrelimab versus chemotherapy and adebrelimab in advanced esophageal squamous cell carcinoma
CTR20263014Phase 2Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Sep 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of SHR-9839 in Esophageal Squamous Cell Carcinoma (ESCC) (3 arms), sponsored by Suzhou Shengdiya Biopharmaceuticals. Primary endpoint: Objective response rate. Started Sep 2026; status: active.
02
Drugs
SHR-9839
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20263014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263014.